Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies
Alessio Gerussi, Daphne D’Amato, Laura Cristoferi and 3 more
Annals of Hepatology · 2020
doi:10.1016/j.aohep.2019.09.009 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Primary biliary cholangitis and primary sclerosing cholangitis are rare diseases affecting the bile ducts and the liver. The limited knowledge of their pathogenesis leads to limited therapeutic options. Nevertheless, the landscape of novel therapies for these cholangiopathies is now rapidly changing, providing new treatment opportunities for patients and clinicians involved in their care. The aim of this review is to summarize the evidence of novel molecules under investigation for primary biliary cholangitis and primary sclerosing cholangitis and to discuss how they can potentially change current treatment paradigms.
Abstract licence: CC BY-NC-ND
References150
40 more references, whose wording the paper’s licence keeps private.
All 150 referencesReads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.